Skip to main content
. 2023 Aug 9;7(6):102163. doi: 10.1016/j.rpth.2023.102163

Table 2.

Annualized bleeding rates of subjects during the first and last 6 months of rFVIIIFc prophylaxis in A-LONG/ASPIRE and rFIXFc prophylaxis in B-LONG/B-YOND.

Median (IQR) rFVIIIFc prophylaxis in A-LONG/ASPIRE (N = 67)
 rFIXFc prophylaxis in B-LONG/B-YOND (N = 50)
First 6 months Last 6 months First 6 months Last 6 months
Overall ABR 0.0 (0.0-2.0) 0.0 (0.0-2.0) 2.0 (0.0-6.0) 2.0 (0.0-4.0)
AJBR 0.0 (0.0-2.0) 0.0 (0.0-2.0) 1.0 (0.0-4.0) 0.0 (0.0-2.0)
AJSBR 0.0 (0.0-0.0) 0.0 (0.0-2.0) 0.0 (0.0-2.0) 0.0 (0.0-0.0)

ABR, annualized bleeding rate; AJBR, joint annualized bleeding rate; AJSBR, spontaneous joint annualized bleeding rate; IQR, interquartile range; rFVIIIFc, recombinant factor VIII Fc fusion protein; rFIXFc, recombinant factor IX Fc fusion protein.